News | February 05, 2022
IOL Chemicals and Pharmaceuticals Q3FY22 PAT at Rs. 40.07 crore
IOL Chemicals and Pharmaceuticals has reported standalone financial results for the period ended December 31, 2021
IOL Chemicals and Pharmaceuticals has reported standalone financial results for the period ended December 31, 2021
The audit is a PAI for two of its product applications filed from this facility
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
Glenmark’s current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA
Torrent Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.
First launches expected in H1 2022
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
The company has 47 ANDA's pending approval with the U.S.FDA
The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival
Subscribe To Our Newsletter & Stay Updated
